CAJ | 학술논문

目的：观察多西他赛联合卡铂21 d 方案（TC 方案）二、三线治疗转移性三阴乳腺癌（ATNBC）患者的疗效和不良反应。方法37例蒽环类耐药的晚期 ATNBC 患者，多西他赛70 mg／m2，第1天静脉滴注；卡铂曲线下面积（AUC）＝5，第1天静脉滴注，21 d 为1个疗程，直到疾病进展或无法耐受或最多接受6个周期化疗。结果37例患者共完成147个周期化疗，中位化疗周期为4个周期。均可评价疗效和不良反应。其中完全缓解（CR）0例，部分缓解（PR）12例（32．43％），稳定（SD）11例（29．73％），进展14例（PD）（41.18％）。有效率（RR ＝CR ＋PR）为32．43％，疾病控制率（CR ＋PR ＋SD）为62．15％，中位疾病进展时间（TTP）3．9个月（95％CI：4～8个月），中位总生存时间（OS）10．0个月，至随访结束，仍有3例患者无进展生存。治疗后主要不良反应为血液学毒性（白细胞减少51．53％）和消化道反应（56．76％）。结论TC 方案治疗晚期 ATNBC 患者安全有效，不良反应可以耐受。
목적：관찰다서타새연합잡박21 d 방안（TC 방안）이、삼선치료전이성삼음유선암（ATNBC）환자적료효화불량반응。방법37례은배류내약적만기 ATNBC 환자，다서타새70 mg／m2，제1천정맥적주；잡박곡선하면적（AUC）＝5，제1천정맥적주，21 d 위1개료정，직도질병진전혹무법내수혹최다접수6개주기화료。결과37례환자공완성147개주기화료，중위화료주기위4개주기。균가평개료효화불량반응。기중완전완해（CR）0례，부분완해（PR）12례（32．43％），은정（SD）11례（29．73％），진전14례（PD）（41.18％）。유효솔（RR ＝CR ＋PR）위32．43％，질병공제솔（CR ＋PR ＋SD）위62．15％，중위질병진전시간（TTP）3．9개월（95％CI：4～8개월），중위총생존시간（OS）10．0개월，지수방결속，잉유3례환자무진전생존。치료후주요불량반응위혈액학독성（백세포감소51．53％）화소화도반응（56．76％）。결론TC 방안치료만기 ATNBC 환자안전유효，불량반응가이내수。
Objective To observe the clinical efficacy and adverse reactions of docetaxel and carboplatin 21 day regimen (TC)as second -or third -line in treatment of patients with advanced triple -negative breast cancer (ATNBC).Methods 37 ATNBC patients with anthracyclines resistance were given docetaxel 70mg/m2 ,the first day of intravenous drip,carboplatin AUC =5,through intravenous drip on the first day,21 days for a course of treatment, until disease progression or not tolerated or most received six cycles of chemotherapy.Results 147 cycles of chemo-therapy were completed in 37 patients,and the median chemotherapy cycle was 4 cycles.The efficacy and adverse reactions could be evaluated in all patients.Among them,complete remission (CR)in 0 patient,partial remission (PR)in 12 patients (32.43%),stable (SD)in 11 patients (29.73%),and progression (PD)in 14 patients (41.18%).The effective rate(CR +PR)was 32.43%.The disease control rate (CR +PR +SD)was 62.15%,median TTP was 3.9 months (95%CI:4 -8months),and median OS was 10 months.Until the end of follow -up,there were 3 patients with no progress.The main adverse reactions were hematological toxicity (51.53%)and gastrointestinal reaction (56.76%).Conclusion TC regimen is effective and safe in the treatment of patients with ATNBC.